Methotrexate is a medication used by doctors to treat a variety of diseases. The medical community has confirmed the efficacy of methotrexate, but healthcare professionals and patients need to understand the potential side effects of using this potent drug in order to achieve the best treatment results. Among the many possible side effects, the main side effect of methotrexate is hepatotoxicity, which is a toxic effect on the liver. If not properly monitored, the severity can range from mild elevation of liver enzymes to severe liver damage.
Methotrexate belongs to a class of drugs called antimetabolites. The drug functions through its ability to stop dihydrofolate reductase (DHFR) from working which prevents cells from creating DNA and multiplying. Methotrexate functions by stopping the growth of fast-replicating cells through its mechanism which prevents cell division from occurring. Methotrexate's therapeutic effect stems from this mechanism of action, but the same mechanism can also lead to organ toxicity during drug metabolism, especially in the liver.
Figure 1. MTX cellular pharmacology and mechanism of action. (Source: Vermeer E, et al.; 2023)
The three factors which determine side effect occurrence and intensity include drug dosage and administration schedule and delivery method. Low-dose methotrexate is commonly prescribed for autoimmune conditions and is generally well-tolerated. The cancer treatment drug high-dose methotrexate requires patients to receive close medical surveillance because it produces severe side effects which can be managed through folinic acid rescue treatment.
Methotrexate causes liver toxicity which represents the most dangerous side effect that affects patients in clinical practice. The liver becomes damaged through hepatotoxicity which results in three main patterns of liver damage that include elevated liver enzyme levels of ALT and AST and two additional patterns of fatty liver disease and fibrosis and cirrhosis. The risk of liver damage becomes higher when patients receive multiple doses of methotrexate and when their treatment duration becomes longer and when they have conditions like alcohol use and obesity and diabetes and pre-existing liver problems.
People who receive methotrexate treatment for extended periods need to get their liver function tested through LFTs on a regular basis. Physicians can prevent permanent liver damage through early detection of liver enzyme elevations which enables them to modify medication amounts and stop treatment temporarily and start protective strategies.
While hepatotoxicity is the major side effect, methotrexate can also cause a range of other adverse effects that patients should be aware of:
Multiple elements exist which increase the chances of developing side effects from methotrexate treatment. These include:
Healthcare providers use different methods to reduce dangerous side effects which methotrexate causes in patients.
Methotrexate functions as a primary therapeutic agent which treats different cancers and autoimmune disorders because it successfully manages fast cell proliferation and immune system control. The main side effect of hepatotoxicity requires healthcare providers to closely monitor patients while taking steps for prevention. The treatment of other essential side effects which include bone marrow suppression and gastrointestinal problems and pulmonary complications and skin reactions needs specific approaches together with patient education and regular laboratory tests to minimize risks.
Patients who receive methotrexate treatment need to stay in touch with their doctor while they should immediately share any strange body reactions and follow all scheduled medical check-ups. Methotrexate treatment for extended disease control becomes possible through its safe administration which combines therapeutic advantages with proper management of potential adverse effects.
The most dangerous side effect of this medication occurs when it damages liver tissue which leads to elevated liver enzymes and potentially cirrhosis when proper surveillance is absent.
The medication causes side effects which affect bone marrow and lungs and kidneys and skin although these occurrences happen less frequently than liver damage.
The management of side effects requires patients to undergo scheduled blood tests and receive folic acid supplements and doctors should make treatment adjustments and patients need to follow specific lifestyle rules which include reducing their alcohol consumption.
Reference
| Target | Cat. No. | Product Name | Host | Application | |
| MTX | DPATB-H81809 | Anti-Methotrexate polyclonal antibody | Goat | ELISA, RIA | Inquiry |
| DMAB-WZ0004 | Anti-Methotrexate monoclonal antibody | Mouse | IA | Inquiry | |
| DPABY-912 | Anti-Methotrexate polyclonal antibody | Sheep | ELISA, Pr* | Inquiry | |
| DPABY-070 | Anti-Methotrexate (C-terminal) polyclonal antibody | Sheep | ELISA | Inquiry | |
| DMABB-JX341 | Mouse Anti-Methotrexate monoclonal antibody, clone MTX | Mouse | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| MTX | DAGB319 | Methotrexate [HRP] | HRP | IA | Inquiry |
| DAGA-351B | Methotrexate [BSA] | BSA | LFIA | Inquiry | |
| DAGA-351K | Methotrexate [KLH] | KLH | Immunogen | Inquiry | |
| DWT109 | Methotrexate Standard solution | N/A | Inquiry | ||
| DAG-WZ3635O | Methotrexate [OVA] | OVA | IA | Inquiry |
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| MTX | DEIA-US209 | Methotrexate ELISA kit | 96T | Human, mouse, rat | Quantitative | Serum, plasma and urine | Inquiry |
| DEIA-XYZ209 | Methotrexate ELISA kit | 96T | Human | Quantitative | Serum, Plasma | Inquiry |